Lates News

Each AI flash, Southwest Securities released a research report on August 28, giving a hold rating to Beida Pharmaceutical (300558.SZ). The rating reasons mainly include: 1) rising costs leading to a decrease in net profit margin, maintaining a high gross profit margin, and EBITDA highlighting the sustainability of core business; 2) the commercialization of innovative cancer drugs accelerating, core products maintaining market leadership; 3) smooth progress in the research pipeline, with long-term potential of multiple varieties waiting to be released. (Daily Economic News)